TR201900130T4 - Pharmaceutical compositions for combination therapy. - Google Patents
Pharmaceutical compositions for combination therapy. Download PDFInfo
- Publication number
- TR201900130T4 TR201900130T4 TR2019/00130T TR201900130T TR201900130T4 TR 201900130 T4 TR201900130 T4 TR 201900130T4 TR 2019/00130 T TR2019/00130 T TR 2019/00130T TR 201900130 T TR201900130 T TR 201900130T TR 201900130 T4 TR201900130 T4 TR 201900130T4
- Authority
- TR
- Turkey
- Prior art keywords
- pharmaceutical compositions
- combination therapy
- tesofensin
- tesofensine
- metoprolol
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 230000037396 body weight Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 abstract 1
- 229960002237 metoprolol Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- VCVWXKKWDOJNIT-ZOMKSWQUSA-N tesofensine Chemical compound C1([C@H]2C[C@@H]3CC[C@@H](N3C)[C@@H]2COCC)=CC=C(Cl)C(Cl)=C1 VCVWXKKWDOJNIT-ZOMKSWQUSA-N 0.000 abstract 1
- 229950009970 tesofensine Drugs 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Bu buluş, gıda alımı ve vücut kilo kaybı üzerinde güçlü inhibitör etkinliğini etkilenmemiş bırakırken Tesofensine'nin kardiyovasküler yan etkilerini önlemeye yönelik Tesofensin ve Metoprolol'ün terapötik olarak etkili bir kombinasyonunu içeren farmasötik bileşimlerin kullanımı ile ilgilidir.The present invention relates to the use of pharmaceutical compositions containing a therapeutically effective combination of Tesofensin and Metoprolol for preventing the cardiovascular side effects of Tesofensine while leaving its potent inhibitory activity on food intake and body weight loss unaffected.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261599623P | 2012-02-16 | 2012-02-16 | |
| DKPA201270076 | 2012-02-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201900130T4 true TR201900130T4 (en) | 2019-02-21 |
Family
ID=67353807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2019/00130T TR201900130T4 (en) | 2012-02-16 | 2013-02-14 | Pharmaceutical compositions for combination therapy. |
Country Status (3)
| Country | Link |
|---|---|
| HU (1) | HUE043019T2 (en) |
| PT (1) | PT2814473T (en) |
| TR (1) | TR201900130T4 (en) |
-
2013
- 2013-02-14 PT PT13703834T patent/PT2814473T/en unknown
- 2013-02-14 HU HUE13703834A patent/HUE043019T2/en unknown
- 2013-02-14 TR TR2019/00130T patent/TR201900130T4/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2814473T (en) | 2019-01-21 |
| HUE043019T2 (en) | 2019-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015500064B1 (en) | Imidazotriazinecarbonitriles useful as kinase inhibitors | |
| GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
| EP2827869A4 (en) | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | |
| IL239355A0 (en) | Gamma-hydroxybutyrate compositions and their use for the treatment of disorders | |
| EA201391033A1 (en) | BACE-2 INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS | |
| UA110213C2 (en) | Use of sigma-ligand induced opioid hyperalgesia | |
| EA201591198A1 (en) | ANTIBODIES TO GDF15 | |
| EA201491532A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR USE IN COMPLEX THERAPY | |
| UA108101C2 (en) | N3-substituted N1-sulfonyl-5-fluoropyrimidinone derivatives | |
| PH12016501160A1 (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
| MX2014014832A (en) | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase. | |
| MX348451B (en) | Derivatives of n- [(1h-pyrazol-1-yl) aryl] - 1h - indole or 1h - indazole - 3 - carboxamide, their preparation and their use as p2y12 antagonists. | |
| NZ709153A (en) | Pyrimidinone derivatives having human neutrophil elastase inhibitory activity | |
| UA107666C2 (en) | The use of l-serine as a drug for preventing and/or treating an inflammatory response of the skin | |
| BR112012030482A2 (en) | type 2 diabetes treatment | |
| MA35816B1 (en) | Aniline derivatives, their preparation and their therapeutic application | |
| PH12014501140B1 (en) | Protective agent for keratoconjunctiva or suppressive agent for keratoconjunctival disorder | |
| MX365192B (en) | Bendamustine derivatives and related compounds, and medical use thereof cancer therapy. | |
| MX2015014470A (en) | Combretastatin analogs. | |
| BR112015009602A2 (en) | somatostatin-dopamine chimeric analogs | |
| MX2015005312A (en) | 1 h-indole-3-carboxamide derivatives and use thereof as p2y12 antagonists. | |
| PH12014502259A1 (en) | Association of beta-glucans and arabinoxylans | |
| TR201900130T4 (en) | Pharmaceutical compositions for combination therapy. | |
| TN2014000484A1 (en) | Dronedarone for use in leishmaniasis, formulations and associations for use in leishmaniasis. | |
| MX2013006526A (en) | Dosages of arylsulfonamide derivatives. |